A citation-based method for searching scientific literature

Torben Biester, Olga Kordonouri, Thomas Danne. Diabetes Obes Metab 2019
Times Cited: 5







List of co-cited articles
13 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors.
Thomas Danne, Satish Garg, Anne L Peters, John B Buse, Chantal Mathieu, Jeremy H Pettus, Charles M Alexander, Tadej Battelino, F Javier Ampudia-Blasco, Bruce W Bode,[...]. Diabetes Care 2019
81
80

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Diabetes Care 2018
70
60

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Steven C Griffen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Lancet Diabetes Endocrinol 2017
136
60

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
40

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
40

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
James F List, Vincent Woo, Enrique Morales, Weihua Tang, Fred T Fiedorek. Diabetes Care 2009
410
40

Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).
T R Pieber, S Famulla, J Eilbracht, J Cescutti, N Soleymanlou, O E Johansen, H J Woerle, U C Broedl, S Kaspers. Diabetes Obes Metab 2015
96
40

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
40

Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
Satish K Garg, Robert R Henry, Phillip Banks, John B Buse, Melanie J Davies, Gregory R Fulcher, Paolo Pozzilli, Diane Gesty-Palmer, Pablo Lapuerta, Rafael Simó,[...]. N Engl J Med 2017
172
40

Gender and Age - Dependent effect of type 1 diabetes on obesity and altered body composition in young adults.
Agnieszka Szadkowska, Anna Madej, Katarzyna Ziółkowska, Małgorzata Szymańska, Krzysztof Jeziorny, Beata Mianowska, Iwona Pietrzak. Ann Agric Environ Med 2015
18
40

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.
Chantal Mathieu, Paresh Dandona, Pieter Gillard, Peter Senior, Christoph Hasslacher, Eiichi Araki, Marcus Lind, Stephen C Bain, Serge Jabbour, Niki Arya,[...]. Diabetes Care 2018
96
40

Temporal patterns in overweight and obesity in Type 1 diabetes.
B Conway, R G Miller, T Costacou, L Fried, S Kelsey, R W Evans, T J Orchard. Diabet Med 2010
162
40

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
Ele Ferrannini, Elza Muscelli, Silvia Frascerra, Simona Baldi, Andrea Mari, Tim Heise, Uli C Broedl, Hans-Juergen Woerle. J Clin Invest 2014
550
40

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.
David Zi Cherney, Bruce A Perkins, Nima Soleymanlou, Ronnie Har, Nora Fagan, Odd Erik Johansen, Hans-Juergen Woerle, Maximilian von Eynatten, Uli C Broedl. Cardiovasc Diabetol 2014
259
20

SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.
Silvio E Inzucchi, Bernard Zinman, Christoph Wanner, Roberto Ferrari, David Fitchett, Stefan Hantel, Rosa-Maria Espadero, Hans-Jürgen Woerle, Uli C Broedl, Odd Erik Johansen. Diab Vasc Dis Res 2015
225
20

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
Kåre I Birkeland, Marit E Jørgensen, Bendix Carstensen, Frederik Persson, Hanne L Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Thomas Nyström, Jan W Eriksson,[...]. Lancet Diabetes Endocrinol 2017
161
20


SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.
Ele Ferrannini, Anna Solini. Nat Rev Endocrinol 2012
233
20

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
Jan Bolinder, Östen Ljunggren, Joel Kullberg, Lars Johansson, John Wilding, Anna Maria Langkilde, Jennifer Sugg, Shamik Parikh. J Clin Endocrinol Metab 2012
425
20

Effects of sodium glucose cotransporter type 2 inhibitors on heart failure.
Michael E Nassif, Mikhail Kosiborod. Diabetes Obes Metab 2019
6
20


Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.
Ralph A DeFronzo, Luke Norton, Muhammad Abdul-Ghani. Nat Rev Nephrol 2017
165
20

The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -/- mice fed a western diet.
Ji Hye Han, Tae Jung Oh, Ghayoung Lee, Hyo Jin Maeng, Dong Hwa Lee, Kyoung Min Kim, Sung Hee Choi, Hak Chul Jang, Hye Seung Lee, Kyong Soo Park,[...]. Diabetologia 2017
76
20

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
Martin Ridderstråle, Knut Robert Andersen, Cordula Zeller, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
209
20

CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Ele Ferrannini, Michael Mark, Eric Mayoux. Diabetes Care 2016
421
20

Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade.
Michael A Weber, Traci A Mansfield, Federica Alessi, Nayyar Iqbal, Shamik Parikh, Agata Ptaszynska. Blood Press 2016
50
20

Glucagon and heart in type 2 diabetes: new perspectives.
Antonio Ceriello, Stefano Genovese, Edoardo Mannucci, Edoardo Gronda. Cardiovasc Diabetol 2016
36
20


Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk.
Bernard Zinman, Silvio E Inzucchi, John M Lachin, Christoph Wanner, David Fitchett, Sven Kohler, Michaela Mattheus, Hans J Woerle, Uli C Broedl, Odd Erik Johansen,[...]. Stroke 2017
64
20

SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta-analysis.
Man Guo, Jingya Ding, Jingsong Li, Jiying Wang, Ting Zhang, Cuiping Liu, Wei Huang, Yang Long, Chenlin Gao, Yong Xu. Diabetes Obes Metab 2018
18
20

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetes Care 2018
799
20

Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?
Rosalie A Scholtes, Michaël J B van Baar, Yuliya Lytvyn, Petter Bjornstad, Max Nieuwdorp, David Z I Cherney, Daniël H van Raalte. Diabetes Obes Metab 2019
6
20

Degree of ketonaemia and its association with insulin resistance after dapagliflozin treatment in type 2 diabetes.
S H Min, T J Oh, S-I Baek, D-H Lee, K M Kim, J H Moon, S H Choi, K S Park, H C Jang, S Lim. Diabetes Metab 2018
15
20

A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors.
Emily Brown, Surya P Rajeev, Daniel J Cuthbertson, John P H Wilding. Diabetes Obes Metab 2019
19
20

Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice.
Bowen Lin, Nobutaka Koibuchi, Yu Hasegawa, Daisuke Sueta, Kensuke Toyama, Ken Uekawa, MingJie Ma, Takashi Nakagawa, Hiroaki Kusaka, Shokei Kim-Mitsuyama. Cardiovasc Diabetol 2014
147
20

What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition.
Jessica A Dominguez Rieg, Timo Rieg. Diabetes Obes Metab 2019
11
20

Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients.
Hussein Al Jobori, Giuseppe Daniele, John Adams, Eugenio Cersosimo, Curtis Triplitt, Ralph A DeFronzo, Muhammad Abdul-Ghani. Diabetes Obes Metab 2017
32
20


Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes.
Hirotaka Watada, Masanari Shiramoto, Shinya Ueda, Weifeng Tang, Michiko Asano, Fredrik Thorén, Hyosung Kim, Toshitaka Yajima, David W Boulton, Eiichi Araki. Diabetes Obes Metab 2019
6
20

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial.
R R Henry, A V Murray, M H Marmolejo, D Hennicken, A Ptaszynska, J F List. Int J Clin Pract 2012
192
20

Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT-5): 52-week results from a randomized, open-label, phase III clinical trial.
Eiichi Araki, Hirotaka Watada, Yasuko Uchigata, Osamu Tomonaga, Hitomi Fujii, Hiroshi Ohashi, Tadashi Okabe, Michiko Asano, Fredrik Thoren, Hyosung Kim,[...]. Diabetes Obes Metab 2020
5
20

Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin.
Kristina M Johnsson, Agata Ptaszynska, Bridget Schmitz, Jennifer Sugg, Shamik J Parikh, James F List. J Diabetes Complications 2013
120
20

Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise.
K Kaku, A Kiyosue, S Inoue, N Ueda, T Tokudome, J Yang, A M Langkilde. Diabetes Obes Metab 2014
69
20

Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
Robert R Henry, Julio Rosenstock, Steven Edelman, Sunder Mudaliar, Alexandros-Georgios Chalamandaris, Sreeneeranj Kasichayanula, Allyson Bogle, Nayyar Iqbal, James List, Steven C Griffen. Diabetes Care 2015
142
20

Insulin resistance in type 1 diabetes: what is 'double diabetes' and what are the risks?
S J Cleland, B M Fisher, H M Colhoun, N Sattar, J R Petrie. Diabetologia 2013
87
20



Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials.
Kristina Johnsson, Eva Johnsson, Traci A Mansfield, Yshai Yavin, Agata Ptaszynska, Shamik J Parikh. Postgrad Med 2016
25
20




Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.